Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
BACKGROUND: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
OBJECTIVE: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
CONCLUSION: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current drug targets - 19(2018), 11 vom: 18., Seite 1309-1317 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akagi, Daisuke [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.10.2019 Date Revised 25.10.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389450118666171013101815 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277036046 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277036046 | ||
| 003 | DE-627 | ||
| 005 | 20231225013318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389450118666171013101815 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0923.xml |
| 035 | |a (DE-627)NLM277036046 | ||
| 035 | |a (NLM)29034833 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akagi, Daisuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2019 | ||
| 500 | |a Date Revised 25.10.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a BACKGROUND: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture | ||
| 520 | |a OBJECTIVE: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation | ||
| 520 | |a CONCLUSION: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Abdominal aortic aneurysm (AAA) | |
| 650 | 4 | |a drug therapy | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a intraluminal thrombus | |
| 650 | 4 | |a omega-3 polyunsaturated fatty acid (PUFA) | |
| 650 | 4 | |a resolvin. | |
| 650 | 7 | |a Fatty Acids, Omega-3 |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Docosahexaenoic Acids |2 NLM | |
| 650 | 7 | |a 25167-62-8 |2 NLM | |
| 700 | 1 | |a Hoshina, Katsuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Conte, Micheal S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d 2000 |g 19(2018), 11 vom: 18., Seite 1309-1317 |w (DE-627)NLM113669291 |x 1873-5592 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:11 |g day:18 |g pages:1309-1317 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389450118666171013101815 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 11 |b 18 |h 1309-1317 | ||